Outpatient Oncology Infusion Market (By Product: Infusion Pumps, Intravenous Sets, IV Cannulas, Needleless Connectors; By Application: Lung Cancer, Liver Cancer, Breast Cancer, Prostate Cancer; By Therapy: Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy; By Mode: Intramuscular (IM), Intravenous (IV), Subcutaneous) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2033
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Outpatient Oncology Infusion Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Outpatient Oncology Infusion Market, by Product, 2024-2033
8.1.1. Infusion Pumps
8.1.1.1. Market Revenue and Forecast (2021-2033)
8.1.2. Intravenous Sets
8.1.2.1. Market Revenue and Forecast (2021-2033)
8.1.3. IV Cannulas
8.1.3.1. Market Revenue and Forecast (2021-2033)
8.1.4. Needleless Connectors
8.1.4.1. Market Revenue and Forecast (2021-2033)
9.1. Outpatient Oncology Infusion Market, by Application, 2024-2033
9.1.1. Lung Cancer
9.1.1.1. Market Revenue and Forecast (2021-2033)
9.1.2. Liver Cancer
9.1.2.1. Market Revenue and Forecast (2021-2033)
9.1.3. Breast Cancer
9.1.3.1. Market Revenue and Forecast (2021-2033)
9.1.4. Prostate Cancer
9.1.4.1. Market Revenue and Forecast (2021-2033)
10.1. Outpatient Oncology Infusion Market, by Therapy, 2024-2033
10.1.1. Chemotherapy
10.1.1.1. Market Revenue and Forecast (2021-2033)
10.1.2. Targeted Therapy
10.1.2.1. Market Revenue and Forecast (2021-2033)
10.1.3. Immunotherapy
10.1.3.1. Market Revenue and Forecast (2021-2033)
10.1.4. Hormonal Therapy
10.1.4.1. Market Revenue and Forecast (2021-2033)
11.1. Outpatient Oncology Infusion Market, by Mode, 2024-2033
11.1.1. Intramuscular (IM)
11.1.1.1. Market Revenue and Forecast (2021-2033)
11.1.2. Intravenous (IV)
11.1.2.1. Market Revenue and Forecast (2021-2033)
11.1.3. Subcutaneous
11.1.3.1. Market Revenue and Forecast (2021-2033)
12.1. North America
12.1.1. Market Revenue and Forecast, by Product (2021-2033)
12.1.2. Market Revenue and Forecast, by Application (2021-2033)
12.1.3. Market Revenue and Forecast, by Therapy (2021-2033)
12.1.4. Market Revenue and Forecast, by Mode (2021-2033)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Product (2021-2033)
12.1.5.2. Market Revenue and Forecast, by Application (2021-2033)
12.1.5.3. Market Revenue and Forecast, by Therapy (2021-2033)
12.1.5.4. Market Revenue and Forecast, by Mode (2021-2033)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Product (2021-2033)
12.1.6.2. Market Revenue and Forecast, by Application (2021-2033)
12.1.6.3. Market Revenue and Forecast, by Therapy (2021-2033)
12.1.6.4. Market Revenue and Forecast, by Mode (2021-2033)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Product (2021-2033)
12.2.2. Market Revenue and Forecast, by Application (2021-2033)
12.2.3. Market Revenue and Forecast, by Therapy (2021-2033)
12.2.4. Market Revenue and Forecast, by Mode (2021-2033)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Product (2021-2033)
12.2.5.2. Market Revenue and Forecast, by Application (2021-2033)
12.2.5.3. Market Revenue and Forecast, by Therapy (2021-2033)
12.2.5.4. Market Revenue and Forecast, by Mode (2021-2033)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Product (2021-2033)
12.2.6.2. Market Revenue and Forecast, by Application (2021-2033)
12.2.6.3. Market Revenue and Forecast, by Therapy (2021-2033)
12.2.6.4. Market Revenue and Forecast, by Mode (2021-2033)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Product (2021-2033)
12.2.7.2. Market Revenue and Forecast, by Application (2021-2033)
12.2.7.3. Market Revenue and Forecast, by Therapy (2021-2033)
12.2.7.4. Market Revenue and Forecast, by Mode (2021-2033)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Product (2021-2033)
12.2.8.2. Market Revenue and Forecast, by Application (2021-2033)
12.2.8.3. Market Revenue and Forecast, by Therapy (2021-2033)
12.2.8.4. Market Revenue and Forecast, by Mode (2021-2033)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Product (2021-2033)
12.3.2. Market Revenue and Forecast, by Application (2021-2033)
12.3.3. Market Revenue and Forecast, by Therapy (2021-2033)
12.3.4. Market Revenue and Forecast, by Mode (2021-2033)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Product (2021-2033)
12.3.5.2. Market Revenue and Forecast, by Application (2021-2033)
12.3.5.3. Market Revenue and Forecast, by Therapy (2021-2033)
12.3.5.4. Market Revenue and Forecast, by Mode (2021-2033)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Product (2021-2033)
12.3.6.2. Market Revenue and Forecast, by Application (2021-2033)
12.3.6.3. Market Revenue and Forecast, by Therapy (2021-2033)
12.3.6.4. Market Revenue and Forecast, by Mode (2021-2033)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Product (2021-2033)
12.3.7.2. Market Revenue and Forecast, by Application (2021-2033)
12.3.7.3. Market Revenue and Forecast, by Therapy (2021-2033)
12.3.7.4. Market Revenue and Forecast, by Mode (2021-2033)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Product (2021-2033)
12.3.8.2. Market Revenue and Forecast, by Application (2021-2033)
12.3.8.3. Market Revenue and Forecast, by Therapy (2021-2033)
12.3.8.4. Market Revenue and Forecast, by Mode (2021-2033)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Product (2021-2033)
12.4.2. Market Revenue and Forecast, by Application (2021-2033)
12.4.3. Market Revenue and Forecast, by Therapy (2021-2033)
12.4.4. Market Revenue and Forecast, by Mode (2021-2033)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Product (2021-2033)
12.4.5.2. Market Revenue and Forecast, by Application (2021-2033)
12.4.5.3. Market Revenue and Forecast, by Therapy (2021-2033)
12.4.5.4. Market Revenue and Forecast, by Mode (2021-2033)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Product (2021-2033)
12.4.6.2. Market Revenue and Forecast, by Application (2021-2033)
12.4.6.3. Market Revenue and Forecast, by Therapy (2021-2033)
12.4.6.4. Market Revenue and Forecast, by Mode (2021-2033)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Product (2021-2033)
12.4.7.2. Market Revenue and Forecast, by Application (2021-2033)
12.4.7.3. Market Revenue and Forecast, by Therapy (2021-2033)
12.4.7.4. Market Revenue and Forecast, by Mode (2021-2033)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Product (2021-2033)
12.4.8.2. Market Revenue and Forecast, by Application (2021-2033)
12.4.8.3. Market Revenue and Forecast, by Therapy (2021-2033)
12.4.8.4. Market Revenue and Forecast, by Mode (2021-2033)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Product (2021-2033)
12.5.2. Market Revenue and Forecast, by Application (2021-2033)
12.5.3. Market Revenue and Forecast, by Therapy (2021-2033)
12.5.4. Market Revenue and Forecast, by Mode (2021-2033)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Product (2021-2033)
12.5.5.2. Market Revenue and Forecast, by Application (2021-2033)
12.5.5.3. Market Revenue and Forecast, by Therapy (2021-2033)
12.5.5.4. Market Revenue and Forecast, by Mode (2021-2033)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Product (2021-2033)
12.5.6.2. Market Revenue and Forecast, by Application (2021-2033)
12.5.6.3. Market Revenue and Forecast, by Therapy (2021-2033)
12.5.6.4. Market Revenue and Forecast, by Mode (2021-2033)
13.1. B. Braun Melsungen AG
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Baxter
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Becton
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Dickinson and Company
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Fresenius Kabi
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. ICU Medical, Inc
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. IRadimed Corporation
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Nipro Corporation
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Terumo Corporation.
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Smith's Medical
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample